LUCAS MEREDITH: Open Payments
NPI 1841902053 · RICHLAND, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,015 in 136 payments from 23 companies in 2025. Trend: 2023 $896 · 2024 $3,378 · 2025 $8,015
Food & beverage: $3,635Consulting: $2,714Travel & lodging: $1,666
| Company | Payments | Amount |
|---|---|---|
| BioCryst Pharmaceuticals, Inc. | 13 | $4,687 |
| GENZYME CORPORATION | 17 | $531 |
| AstraZeneca Pharmaceuticals LP | 22 | $512 |
| Regeneron Healthcare Solutions, Inc. | 15 | $287 |
| Novartis Pharmaceuticals Corporation | 12 | $282 |
| Blueprint Medicines Corporation | 4 | $199 |
| Ionis Pharmaceuticals, Inc. | 3 | $196 |
| LEO Pharma Inc. | 3 | $153 |
| Genentech USA, Inc. | 2 | $141 |
| GlaxoSmithKline, LLC. | 12 | $140 |
Products named: ORLADEYO, DUPIXENT, AIRSUPRA, AYVAKIT, XOLAIR, Rhapsido, TEZSPIRE, DAWNZERA.
Industry payments across WA — which companies pay providers there.
